Tirzepatide for Sleep Apnea: SURMOUNT-OSA Trial Results Explained

Tirzepatide cut sleep-apnea breathing interruptions by about 25-29 events per hour vs about 5 on placebo.

This article walks through the N Engl J Med (2024) paper in plain English: what was studied, what changed, what the limits are, and what it does not prove. Full citation and DOI link are at the end, with a PubMed record.

What the study found

SURMOUNT-OSA was two phase 3, randomized, double-blind, placebo-controlled trials in adults with obesity and moderate-to-severe obstructive sleep apnea, published in NEJM in 2024. One trial enrolled people not using CPAP and one enrolled people on CPAP, and each was treated with tirzepatide or placebo for 52 weeks.

The apnea-hypopnea index fell by 25.3 events per hour with tirzepatide vs 5.3 with placebo in the no-CPAP trial, and 29.3 vs 5.5 in the CPAP trial, with improvements in oxygen burden, hsCRP and blood pressure. The trials used brand-name tirzepatide; compounded versions are not FDA-approved and were not studied.

Key finding (from the study record): AHI -25.3 vs -5.3 events/hr (trial 1, no CPAP) and -29.3 vs -5.5 (trial 2, on CPAP); also lower hsCRP and systolic BP.

How the study was done

• Design: Two phase 3 double-blind RCTs (SURMOUNT-OSA)
• Who was studied: Adults with moderate-severe OSA and obesity (mean AHI ~50)
• Journal / year: N Engl J Med (2024)
• First author: Malhotra A et al.

From the abstract: BACKGROUND: Obstructive sleep apnea is characterized by disordered breathing during sleep and is associated with major cardiovascular complications; excess adiposity is an etiologic risk factor. Tirzepatide may be a potential treatment. METHODS: We conducted two phase 3, double-blind, randomized, controlled trials involving adults with moderate-to-severe obstructive sleep apnea and obesity.

What it means — and what it does not

Useful takeaway: Tirzepatide cut sleep-apnea breathing interruptions by about 25-29 events per hour vs about 5 on placebo.

Limits and caveats: Obese adults with moderate-severe OSA; brand-name drug (now FDA-approved for OSA as Zepbound).

This evidence can inform a conversation with a licensed provider. It is not a guarantee of similar results for you, and it is not a recommendation to start, stop, or change any medication on your own.

Compounded-drug note: The trial used a branded product. If a compounded GLP-1 is discussed later, it is not FDA-approved and is not the same product studied in the branded trial.

Related research we cite

• Tirzepatide for Obesity Treatment and Diabetes Prevention — N Engl J Med (2025); also on PubMed. Takeaway: Over 3 years, people with prediabetes on tirzepatide were about 94% less likely to develop type 2 diabetes.

How this connects to care

AZTRT serves men in Arizona with telehealth evaluation, labs, and provider-guided plans when appropriate. Plans start at $149/month or $357/quarter and include initial labs only. Medication ships three months at a time when prescribed.

Relevant pages on this site:

• Tirzepatide (weight loss) (branded trial drugs are not the same as compounded products, which are not FDA-approved)
• Tirzepatide page (branded trial drugs are not the same as compounded products, which are not FDA-approved)
• TRT program

FAQ

What did this study actually find?

Tirzepatide cut sleep-apnea breathing interruptions by about 25-29 events per hour vs about 5 on placebo. The design was: Two phase 3 double-blind RCTs (SURMOUNT-OSA). Population: Adults with moderate-severe OSA and obesity (mean AHI ~50).

Does this mean I should start treatment?

No. Research informs care; it does not prescribe it. A licensed provider reviews your symptoms, labs, and history before any decision. Results vary.

What are the main limits of this evidence?

Obese adults with moderate-severe OSA; brand-name drug (now FDA-approved for OSA as Zepbound).

Was this the compounded drug some clinics sell?

No. The trial used a branded, FDA-approved product. Compounded copies are not FDA-approved and are not the drug studied.

Keep reading

• One Week of Short Sleep Cut Testosterone 10–15% in Young Men
• SELECT Trial: Semaglutide and Heart Outcomes in Obesity Without Diabetes
• Building Sustainable Habits for Long-Term Weight Loss
• How Do GLP-1 Medications Work? Tirzepatide Explained

Reference

Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024. https://doi.org/10.1056/NEJMoa2404881 · PubMed 38912654.

Next step

Book a free consult with an Arizona-licensed provider. Bring your questions — including anything this study raised for you.

Plans start at $149/month or $357/quarter and include initial labs only. Medication ships three months at a time when prescribed.

Talk to a licensed provider. Results vary. Not medical advice.

Talk to a licensed provider. Results vary. Not medical advice.